385 related articles for article (PubMed ID: 25281607)
1. Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.
Chen E; Schneider RK; Breyfogle LJ; Rosen EA; Poveromo L; Elf S; Ko A; Brumme K; Levine R; Ebert BL; Mullally A
Blood; 2015 Jan; 125(2):327-35. PubMed ID: 25281607
[TBL] [Abstract][Full Text] [Related]
2. Loss of TET2 has dual roles in murine myeloproliferative neoplasms: disease sustainer and disease accelerator.
Kameda T; Shide K; Yamaji T; Kamiunten A; Sekine M; Taniguchi Y; Hidaka T; Kubuki Y; Shimoda H; Marutsuka K; Sashida G; Aoyama K; Yoshimitsu M; Harada T; Abe H; Miike T; Iwakiri H; Tahara Y; Sueta M; Yamamoto S; Hasuike S; Nagata K; Iwama A; Kitanaka A; Shimoda K
Blood; 2015 Jan; 125(2):304-15. PubMed ID: 25395421
[TBL] [Abstract][Full Text] [Related]
3. TET2 loss, a rescue of JAK2V617F HSCs.
Vainchenker W; Plo I
Blood; 2015 Jan; 125(2):212-3. PubMed ID: 25573967
[TBL] [Abstract][Full Text] [Related]
4. Description of a knock-in mouse model of JAK2V617F MPN emerging from a minority of mutated hematopoietic stem cells.
Mansier O; Kilani B; Guitart AV; Guy A; Gourdou-Latyszenok V; Marty C; Parrens M; Plo I; Vainchenker W; James C
Blood; 2019 Dec; 134(26):2383-2387. PubMed ID: 31697834
[TBL] [Abstract][Full Text] [Related]
5. Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.
Shepherd MS; Li J; Wilson NK; Oedekoven CA; Li J; Belmonte M; Fink J; Prick JCM; Pask DC; Hamilton TL; Loeffler D; Rao A; Schröder T; Göttgens B; Green AR; Kent DG
Blood; 2018 Aug; 132(8):791-803. PubMed ID: 29991556
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between TET2 Gene SNP rs3733609 C/T and JAK2V617F Allele Burden in Patients with Myeloproliferative Neoplasms].
Xiao X; Liu XL; Shen XH; Deng MY; Liu SF; Zhang GS
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Oct; 27(5):1574-1579. PubMed ID: 31607314
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiling of loss of TET2 and/or JAK2V617F mutant hematopoietic stem cells from mouse models of myeloproliferative neoplasms.
Kameda T; Shide K; Yamaji T; Kamiunten A; Sekine M; Hidaka T; Kubuki Y; Sashida G; Aoyama K; Yoshimitsu M; Abe H; Miike T; Iwakiri H; Tahara Y; Yamamoto S; Hasuike S; Nagata K; Iwama A; Kitanaka A; Shimoda K
Genom Data; 2015 Jun; 4():102-8. PubMed ID: 26484191
[TBL] [Abstract][Full Text] [Related]
8. Hematopoietic clonal dominance, stem cell mutations, and evolutionary pattern of JAK2V617F allele burden in polycythemia vera.
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Camacho L; Fernández-Rodríguez C; Pairet S; Longarón R; Ancochea Á; Senín A; Florensa L; Besses C
Eur J Haematol; 2015 Mar; 94(3):251-7. PubMed ID: 25082530
[TBL] [Abstract][Full Text] [Related]
9. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
Dunbar A; Nazir A; Levine R
Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
[TBL] [Abstract][Full Text] [Related]
10. Self-renewal of single mouse hematopoietic stem cells is reduced by JAK2V617F without compromising progenitor cell expansion.
Kent DG; Li J; Tanna H; Fink J; Kirschner K; Pask DC; Silber Y; Hamilton TL; Sneade R; Simons BD; Green AR
PLoS Biol; 2013; 11(6):e1001576. PubMed ID: 23750118
[TBL] [Abstract][Full Text] [Related]
11. Jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.
Dunbar AJ; Bowman RL; Park YC; O'Connor K; Izzo F; Myers RM; Karzai A; Zaroogian Z; Kim WJ; Fernández-Maestre I; Waarts MR; Nazir A; Xiao W; Codilupi T; Brodsky M; Farina M; Cai L; Cai SF; Wang B; An W; Yang JL; Mowla S; Eisman SE; Hanasoge Somasundara AV; Glass JL; Mishra T; Houston R; Guzzardi E; Martinez Benitez AR; Viny AD; Koche RP; Meyer SC; Landau DA; Levine RL
Cancer Discov; 2024 May; 14(5):737-751. PubMed ID: 38230747
[TBL] [Abstract][Full Text] [Related]
12. The JAK2 mutation.
Merchant S
Int Rev Cell Mol Biol; 2021; 365():117-162. PubMed ID: 34756242
[TBL] [Abstract][Full Text] [Related]
13. New mutations and pathogenesis of myeloproliferative neoplasms.
Vainchenker W; Delhommeau F; Constantinescu SN; Bernard OA
Blood; 2011 Aug; 118(7):1723-35. PubMed ID: 21653328
[TBL] [Abstract][Full Text] [Related]
14. Circulating CD133+/–CD34– Have Increased c-
Uslu Bıçak İ; Tokcan B; Yavuz AS; Tokdemir SS
Turk J Haematol; 2023 Feb; 40(1):28-36. PubMed ID: 36458557
[TBL] [Abstract][Full Text] [Related]
15. Molecular aspects of myeloproliferative neoplasms.
Delhommeau F; Jeziorowska D; Marzac C; Casadevall N
Int J Hematol; 2010 Mar; 91(2):165-73. PubMed ID: 20186505
[TBL] [Abstract][Full Text] [Related]
16. Distinct effects of ruxolitinib and interferon-alpha on murine JAK2V617F myeloproliferative neoplasm hematopoietic stem cell populations.
Austin RJ; Straube J; Bruedigam C; Pali G; Jacquelin S; Vu T; Green J; Gräsel J; Lansink L; Cooper L; Lee SJ; Chen NT; Lee CW; Haque A; Heidel FH; D'Andrea R; Hill GR; Mullally A; Milsom MD; Bywater M; Lane SW
Leukemia; 2020 Apr; 34(4):1075-1089. PubMed ID: 31732720
[TBL] [Abstract][Full Text] [Related]
17. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
[TBL] [Abstract][Full Text] [Related]
18. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
19. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
[TBL] [Abstract][Full Text] [Related]
20. JAK2V617F Mutant Megakaryocytes Contribute to Hematopoietic Aging in a Murine Model of Myeloproliferative Neoplasm.
Lee S; Wong H; Castiglione M; Murphy M; Kaushansky K; Zhan H
Stem Cells; 2022 Apr; 40(4):359-370. PubMed ID: 35260895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
